Converting Cold into Hot Tumors by Combining Immunotherapies

In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of intralesional injection of a modified human herpes simplex virus and systemic anti-PD-1 treatment resulted in a 62% response rate in patients with metastatic melanoma, accompanied by enhanced T cell infiltra...

Full description

Saved in:
Bibliographic Details
Published in:Cell 2017-09, Vol.170 (6), p.1055-1056
Main Author: Haanen, John B.A.G.
Format: Article
Language:English
Subjects:
Humans
Immunotherapy
Injections, Intralesional
Melanoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of intralesional injection of a modified human herpes simplex virus and systemic anti-PD-1 treatment resulted in a 62% response rate in patients with metastatic melanoma, accompanied by enhanced T cell infiltration in virus-injected lesions. In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of intralesional injection of a modified human herpes simplex virus and systemic anti-PD-1 treatment resulted in a 62% response rate in patients with metastatic melanoma, accompanied by enhanced T cell infiltration in virus-injected lesions.
ISSN:0092-8674
1097-4172
DOI:10.1016/j.cell.2017.08.031